Wungki Park, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X:
“The first map of acquired resistance to the tri-complex RAS(ON) inhibitor daraxonrasib in PDAC published today in Nature Medicine.
The biology converges on KRAS amplification, MAPK reactivation, PI3K signaling, MYC and cell-state plasticity (partial EMT), providing a strong rationale for mechanism-based combination strategies to achieve deeper and more durable responses.
Outstanding work by Ida Aronchik, Sumit Kar, Kevin Lin, Andy Aguirre, Mallika Singh and the entire multidisciplinary team. Excited to see where the field goes next.”
Title: Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer
Authors: Ida Aronchik, Sumit Kar, Yongxian Zhuang, Ethan Ahler, Lick Pui Lai, Vidya Seshadri, Yu Chi Yang, Ashenafi Bulle, Marie Menard, Biswadeep Nayak, Mark P. Labrecque, Julien Dilly, Eejung Kim, Lingyan Jiang, Jason Yano, Urszula N. Wasko, Ciara Helland, Sean Bredeson, Brett Garrick, Yevgeniy Gindin, Brad Sickler, Xing Wei, Kyle Seamon, Jingjing Jiang, Kian-Huat Lim, Matthew Holderfield, Elsa Quintana, Aparna Hegde, Zeena Salman, Alexander Starodub, Alexander Spira, Wungki Park, David S. Hong, Minal Barve, Meredith Pelster, David Sommerhalder, Salman R. Punekar, Ignacio Garrido-Laguna, Brian M. Wolpin, Anirban Maitra, W. Clay Gustafson, Steve Kelsey, Jacqueline A. M. Smith, Kevin K. Lin, Andrew J. Aguirre, Mallika Singh
Read the full article.
Find out more: Daraxonrasib Resistance in Pancreatic Cancer Points to New Combination Strategies